Table 1 Baseline characteristics of IIM patients compared with those of normal controls

Age (years)

49.0 ± 12.0

48.2 ± 15.6

0.232

Males, n (%)

22 (50.0%)

15 (50.0%)

1.000

BMI (kg/m²)

22.4 ± 3.0

22.8 ± 2.8

0.465

Systolic blood pressure, mmHg

122 ± 14

121 ± 11

0.673

Diastolic blood pressure, mmHg

78 ± 8

72 ± 5

0.512

Heart rate

76.5 ± 9.7

74.1 ± 7.2

0.592

Disease duration (years)

0.5 (0.2, 2.0)

–

–

 Proximal muscle weakness, n (%)

41 (93.2%)

–

–

 Rash, n (%)

29 (65.9%)

–

–

 Myalgia, n (%)

23 (52.3%)

–

–

 Dysphagia, n (%)

17 (38.6%)

–

–

 Hypertension, n (%)

6 (13.6%)

–

–

 Diabetes, n (%)

1 (2.3%)

–

–

 Hct

0.40 ± 0.05

0.43 ± 0.03

0.003

 CRP (mg/L)

4.3 (1.7–9.7)

–

–

 ESR (mm/h)

28 (23–47)

–

–

 CK (U/L)

316 (79–2202)

–

–

 CK-MB (ng/mL)

20.6 (5.3–54.0)

–

–

 cTnT (g/L)

96 (40–269)

–

–

 NT-proBNP (pg/mL)

226 (85–747)

–

–

 Steroids, n (%)

44 (100%)

–

–

 Methotrexate, n (%)

22 (50.0%)

–

–

 Cyclophosphamide, n (%)

12 (27.3%)

–

–

 Chloroquine, n (%)

18 (40.9%)

–

–

 Azathioprine, n (%)

4 (9.1%)

–

–

 LVEDVi, mL/m²

82.7 ± 26.6

77.1 ± 13.3

0.300

 LVESVi, mL/m²

33.9 ± 25.1

29.1 ± 8.1

0.428

 LVEF (%)

61.4 ± 11.8

62.0 ± 5.2

0.958

 LVmassi (g/m²)

50.8 ± 15.0

43.6 ± 8.2

0.037

 RVEDVi, mL/m²

80.9 ± 22.2

68.7 ± 18.5

0.042

 RVESVi, mL/m²

38.2 ± 17.1

34. 3 ± 10.5

0.146

 RVEF (%)

53.6 ± 9.8

57.2 ± 5.2

0.055

 T2w ratio

1.3 ± 0.4

1.2 ± 0.4

0.259

 LGE, n (%)

11 (25%)

0

–

 LGE extent, %

12.0 ± 3.1

0

–

 Native T1 mapping-myocardial, ms

1275 ± 82

1199 ± 47

< 0.001

 T2 mapping-myocardial, ms

44.2 ± 4.0

38.3 ± 2.9

< 0.001

 ECV-myocardial, %

32.3 ± 6.2

26.6 ± 2.4

< 0.001

 Native T1 mapping-skeletal, ms

1287 ± 149

1107 ± 70

< 0.001

 T2 mapping-skeletal, ms

34.4 ± 3.1

26.0 ± 1.4

< 0.001

 ECV-skeletal, %

31.1 ± 12.8

13.6 ± 3.1

< 0.001